The Bull Rankings scorecard — our quality-growth score is 85.6 / 100, built from three pillars each graded 0–100 against sector peers: Quality 66, Growth 100, Value 95. At today's price, our reverse-DCF read says the market is implicitly betting on about -6% a year in free-cash-flow growth sustained for a decade — a gauge of how much optimism is already in the stock.
The thesis
The latest quarter was a barnburner — adjusted EPS of $2.21 crushed the $2.05 consensus while sales landed at $266.044M, beating the $260.128M estimate. That revenue growth of 30.9% in the year-ago period, paired with an 11% profit margin and an 18.1% ROE, is the kind of operating leverage that turns top-line surges into real earnings power. Our Bull Rankings model sees it clearly: the Growth pillar clocks in at a perfect 100, the strongest of the three. Yet the price-to-earnings of 16.5× and a PEG of 0.38 already price in a high-growth future. The reverse-DCF is even more revealing: the current price embeds roughly –6% annual free-cash-flow growth for a decade, a stark mismatch to the 30.9% revenue surge.
What the business actually is
ANI is a full-service biopharma that designs, manufactures, and markets branded and generic pharmaceuticals. Its portfolio runs from injectables and softgel capsules to Cortrophin gel, ILUVIEN, and YUTIQ. It also produces oral solids, semi-solids, liquids, topicals, controlled substances, and potent products. Customers include national wholesalers, specialty pharmacies, retail chains, mail-order houses, group purchasing organizations, and hospitals. Cortrophin gel is the current growth engine, while ILUVIEN and YUTIQ anchor high-margin specialty niches.
Why it can (or can't) keep compounding
An ROE of 18.1% on a $1.7B market cap shows capital is being put to work. The 11% profit margin, alongside $173M in trailing free-cash-flow, proves the business can reinvest without strangling cash generation. The Bull Rankings model’s strongest pillar — Growth at 100 — reflects the 30.9% year-over-year revenue climb, largely driven by Cortrophin’s record quarter. ANI’s moat is operational: a diversified manufacturing platform capable of handling potent and controlled substances, a capability hard to replicate quickly. That infrastructure lets ANI capture niche, higher-margin contracts while still scaling generic volumes. A beta of 0.46 underscores defensive pricing power, meaning margins can likely hold even if broader markets wobble.
The valuation question
At $75.76 the stock trades at 16.5× earnings and 1.8× sales, comfortably below specialty-pharma peers. The PEG of 0.38 implies the market expects growth well above the norm embedded in the multiple. The reverse-DCF, however, tells a different story: the price already embeds roughly –6% annual free-cash-flow growth for ten years. In other words, the market is discounting future cash generation far more than the fundamentals justify. Analyst targets sit at $108.38, with a range of $90–$121, reinforcing that the upside is already on many watchlists, but the current price still leaves a sizable gap to those expectations.
The bear case
The weakest pillar in our model is Quality, scoring 66, which signals execution risk. Debt-to-equity stands at 1.05, a level that could strain cash flow if rates rise or if new product launches require funding. The earnings call confirmed forward guidance was trimmed, and shares fell 7.6% on the news despite the beat. If revenue growth slips below 30.9% or if margin pressure erodes the 11% profit rate, the free-cash-flow outlook could indeed turn negative, validating the reverse-DCF’s pessimistic assumption.
What would change our mind
A sustained revenue growth rate above 30.9% for two consecutive quarters would lift the Quality pillar and force the market to reprice the free-cash-flow trajectory upward. A reduction of debt-to-equity below 1.0 would improve balance-sheet resilience and ease cash-flow concerns. Finally, an EPS beat that pushes the P/E below 15× while maintaining the current margin would signal the market is finally aligning price with the growth story, making the valuation gap disappear. Any of these moves would shift the balance toward a stronger bullish conviction.